EUS was inaccurate in staging cT2N0M0 esophageal cancer in this study. Poorly differentiated tumors were more frequently understaged. Adenocarcinoma and absence of lymph node metastases (pN0) were independently predictive of long-term survival. pN0 status was significantly more common in patients undergoing neoadjuvant therapy, but long-term survival was not affected by neoadjuvant therapy. A strategy of neoadjuvant therapy followed by resection may be optimal in this group, especially in patients with disease likely to be understaged.

No abstract

group. Nevertheless, the OS (72.5 months vs. 60.63 months, P ¼ 0.189) and DFS (13.7 months vs. 24.33 months, P ¼ 0.664) were not improved in EGFR-mutant patients with single-station N2 metastasis (Figure 1).Comparison of overall survivall (A,C,E) and disease-free survival (B,D,F) between the PORT and the non-PORT group. PORT¼postoperative radiotherapy. Conclusion: It is necessary for stage IIIA-N2 non-squamous NSCLC patients to receive PORT, especially for EGFR wild-type patients. Meanwhile, PORT can reduce local recurrence and metastasis in EGFR-mutant group, particularly in EGFR-mutant patients with multiple-station N2 metastasis. More prospective studies are needed to clarify the role of PORT in the EGFR-mutant IIIA-N2 non-squamous NSCLC patients.

No abstract

No abstract